The market is driven by licensing agreements, the growing prevalence of chronic diseases, and the vast availability of raw materials
1h Free Analyst Time
The marine pharmaceuticals market is forecasted to grow by USD 1.95 billion during 2023-2028, accelerating at a CAGR of 8.63% during the forecast period. The report on the marine pharmaceuticals market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising consumer demand for natural products, the growing prevalence of chronic diseases, and the presence of rich marine biodiversity.
The marine pharmaceuticals market is segmented as below:
By Product
- Oncology
- Cardiovascular
- Anti-infectives
- Others
By Type
- Health supplements
- Drugs
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the marine pharmaceuticals market covers the following areas:
- Marine pharmaceuticals market sizing
- Marine pharmaceuticals market forecast
- Marine pharmaceuticals market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Executive Summary
The publisher recognizes the following companies as the key players in the global marine pharmaceuticals market: Abbott Laboratories, BASF SE, BeyondSpring Inc., BioMarin Pharmaceutical Inc., Bristol Myers Squibb Co., Croda International Plc, DEKRA SE, EID Parry India Ltd., Eisai Co. Ltd., GFR Pharma, GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Koninklijke DSM NV, MARINE LIFESCIENCES, Merck KGaA, Pfizer Inc., PharmaMar SA, Roquette Freres SA, TerSera Therapeutics LLC, and ZELNOVA ZELTIA S.A..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the rise of antibiotics from marine microbes.'
According to the report, one of the major drivers for this market is the rising consumer demand for natural products.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- BASF SE
- BeyondSpring Inc.
- BioMarin Pharmaceutical Inc.
- Bristol Myers Squibb Co.
- Croda International Plc
- DEKRA SE
- EID Parry India Ltd.
- Eisai Co. Ltd.
- GFR Pharma
- GlaxoSmithKline Plc
- Jazz Pharmaceuticals Plc
- Koninklijke DSM NV
- MARINE LIFESCIENCES
- Merck KGaA
- Pfizer Inc.
- PharmaMar SA
- Roquette Freres SA
- TerSera Therapeutics LLC
- ZELNOVA ZELTIA S.A.